Caribou Biosciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CRBU research report →
Range $1 – $1
Price Chart
About the company
Caribou Biosciences, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to pioneering genome-edited allogeneic cell therapies. These cutting-edge treatments are engineered to address both hematologic malignancies (blood cancers) and solid tumors, serving patients across the United States and internationally.
- CEO
- Rachel E. Haurwitz
- IPO
- 2021
- Employees
- 97
- HQ
- Berkeley, CA, US
Get TickerSpark's AI analysis on CRBU
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $30.71M
- P/E
- -0.33
- PEG
- -0.01
- P/S
- 3.90
- P/B
- 0.48
- EV/EBITDA
- -0.36
- Div Yield
- 0.00%
- Gross Margin
- 93.13%
- Op Margin
- -1140.55%
- Net Margin
- -1085.00%
- ROE
- -102.74%
- ROIC
- -102.68%
Latest fiscal year · YoY change
- Revenue
- $11.16M+11.7%
- Gross Profit
- $7.51M+23.9%
- Op Income
- $-136,194,000
- Net Income
- $-148,125,000+0.7%
- EPS
- $-1.59+3.6%
- OCF Growth
- +19.7%
- FCF Growth
- +22.4%
- 52W High
- $2.49
- 52W Low
- $0.28
- 50D MA
- $0.74
- 200D MA
- $1.55
- Beta
- 2.49
- RSI (14)
- 21
- Avg Volume
- 2.84M
No earnings-call transcripts are available for CRBU yet.
- Free Float
- 91.0%
- Shares Outstanding
- 108.04M
- Float Shares
- 98.31M
of shares held by institutions
145 13F filers
Buy/sell ratio 3.80. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 8.14M | ▲ 327.31K |
| Pfizer Inc | 4.69M | 0 |
| Vanguard Capital Management LLC | 4.43M | ▲ 220.09K |
| Vanguard Group Inc | 4.30M | ▲ 77.27K |
| Mackenzie Financial Corp | 4.07M | ▲ 421.02K |
| Renaissance Technologies LLC | 2.56M | ▼ 217.54K |
| Kynam Capital Management, LP | 2.50M | 0 |
| Geode Capital Management, LLC | 2.44M | ▲ 63.88K |
| State Street Corp | 1.53M | ▼ 106.13K |
| Acadian Asset Management LLC | 1.45M | ▼ 319.75K |
| Bank Of America Corp | 1.41M | ▲ 113.79K |
| Qube Research & Technologies Ltd | 1.12M | ▲ 573.93K |
Held by 119 ETFs
Biggest fund positions in CRBU by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 25, 26 | Kelly Timothy P | sell | 6,228 |
| Feb 20, 26 | Kelly Timothy P | other | 202,500 |
| Feb 20, 26 | Kelly Timothy P | other | 45,000 |
| Feb 24, 26 | Kelly Timothy P | sell | 3,147 |
| Feb 20, 26 | MCCLUNG BARBARA G | other | 45,000 |
| Feb 24, 26 | MCCLUNG BARBARA G | sell | 6,938 |
| Feb 20, 26 | MCCLUNG BARBARA G | other | 202,500 |
| Feb 20, 26 | Khan Ruhi Ahmad | other | 202,500 |
| Feb 20, 26 | Khan Ruhi Ahmad | other | 45,000 |
| Feb 24, 26 | Khan Ruhi Ahmad | sell | 6,938 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CRBU coverage
Recent articles, reports, and earnings notes.
No research on CRBU yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CRBU report →Caribou Biosciences: Stress-Testing The Liquidation Floor And Playing The Shell Exit
seekingalpha.com · Nov 17
Caribou Biosciences (CRBU) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
zacks.com · Nov 12
Caribou Biosciences, Inc. (CRBU) Reports Q3 Loss, Beats Revenue Estimates
zacks.com · Nov 5
Caribou Biosciences Reports Third Quarter 2026 Financial Results
globenewswire.com · Nov 5
Caribou Biosciences, Inc. (CRBU) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
zacks.com · Nov 4
Caribou Biosciences Announces Presentations at the 2026 American Society of Hematology (ASH) Annual Meeting
globenewswire.com · Nov 4
Caribou Biosciences to Evaluate Strategic Alternatives
globenewswire.com · Oct 6
Caribou Biosciences (CRBU) Loses 19.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
zacks.com · Sep 14
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.